SLC Modulator Therapy Prediction via COMT Genotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia and other psychiatric disorders, particularly negative symptoms, are inadequate in addressing persistent and debilitating symptoms like avolition and blunted affect, with existing medications failing to effectively manage these conditions.
Innovation Solution
A method involving the determination of COMT gene alleles, specifically the Val158/108Met locus, to predict the clinical response to solute carrier (SLC) modulators that either increase or decrease proline levels, allowing for personalized treatment approaches by administering appropriate SLC modulators based on genetic and biochemical markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications are used to treat psychiatric disorders, then general treatment coverage is provided, but negative symptoms such as avolition and blunted affect remain persistent and unaddressed
Solution Approach 1:
The patent applies local quality by tailoring treatment to specific patient subgroups based on their COMT genotype. Instead of a uniform treatment approach, the invention identifies that Val/Val homozygotes respond differently to SLC modulators compared to Met allele carriers, thereby addressing negative symptoms effectively in the specific population that requires it while leaving other treatments unchanged for other patients.
2Ease of operation
If a uniform treatment approach is used for all patients, then treatment simplicity is maintained, but individual response variability to SLC modulators is not accounted for
Solution Approach 1:
The patent applies preliminary action by performing COMT genotyping before initiating SLC modulator treatment. This advance genetic assessment allows clinicians to predict which patients will respond favorably to proline-level modulation, enabling personalized treatment selection before therapy begins and avoiding ineffective treatments for Met allele carriers.
3Productivity
If SLC modulators are administered without genetic screening, then treatment accessibility is maximized, but clinical response prediction accuracy is reduced
Solution Approach 1:
The patent applies parameter changes by using COMT genotype as a biomarker parameter to stratify patients into different treatment groups. The Val158Met polymorphism creates distinct pharmacological responses to SLC modulators, and by measuring this genetic parameter, the invention enables accurate prediction of clinical response and optimizes treatment selection.
Data Source
AI summary
The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.